Cargando…

The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia

AIM: was to assess the role of C-KIT, TET1 and TET2 expression in the diagnosis and prognosis of acute myeloblastic leukemia (AML). METHODS: The expression levels of C-KIT, TET1 and TET2 were assessed in the bone marrow (BM) aspirate of 152 AML patients compared to 20 healthy control using quantitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabil, Reem, Hassan, Naglaa M., Abdellateif, Mona S., Gawdat, Rania M., Elshazly, Samar Sami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884250/
https://www.ncbi.nlm.nih.gov/pubmed/36371552
http://dx.doi.org/10.1007/s11033-022-08000-0
_version_ 1784879677849993216
author Nabil, Reem
Hassan, Naglaa M.
Abdellateif, Mona S.
Gawdat, Rania M.
Elshazly, Samar Sami
author_facet Nabil, Reem
Hassan, Naglaa M.
Abdellateif, Mona S.
Gawdat, Rania M.
Elshazly, Samar Sami
author_sort Nabil, Reem
collection PubMed
description AIM: was to assess the role of C-KIT, TET1 and TET2 expression in the diagnosis and prognosis of acute myeloblastic leukemia (AML). METHODS: The expression levels of C-KIT, TET1 and TET2 were assessed in the bone marrow (BM) aspirate of 152 AML patients compared to 20 healthy control using quantitative real-time polymerase chain reaction (qRT-PCR). Data were correlated with the clinico-pathological features of the patients, response to treatment, disease-free survival (DFS), and overall survival (OS) rates. RESULTS: C-KIT, TET1 and TET2 were significantly upregulated in AML patients [0.25 (0–11.6), 0.0113 (0–3.301), and 0.07 (0–4); respectively], compared to the control group [0.013 (0.005–0.250), P < 0.001, 0.001 (0–0.006), P < 0.001, and 0.02 (0.008–0.055), P = 0.019; respectively]. The sensitivity, specificity, and area under curve of of C-KIT were (48.7%, 100%, 0.855; respectively, P = 0.001), and that of TET1 were (63.4%, 100%, 0.897; respectively, P = 0.001), while that of TET2 were (56.8%, 100%, 0.766; respectively, P = 0.019). When combining the three markers, the sensitivity was 77.5%, however it reached the highest sensitivity (78.6%) and specificity (100%) when combining both c-KIT + TET1 together for the diagnosis of AML. C-KIT overexpression associated with shorter DFS (P = 0.05) and increased incidence of relapse (P = 0.019). Lymph nodes involvement [HR = 2.200, P = 0.005] is an independent risk factor for shorter OS rate of AML patients. Increased BM blast % [HR = 7.768, P = 0.002], and FLT3-ITD mutation [HR = 2.989, P = 0.032] are independent risk factors for shorter DSF rate of the patients. CONCLUSION: C-KIT, TET1, and TET2 could be used as possible useful biomarkers for the diagnosis of AML.
format Online
Article
Text
id pubmed-9884250
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-98842502023-01-30 The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia Nabil, Reem Hassan, Naglaa M. Abdellateif, Mona S. Gawdat, Rania M. Elshazly, Samar Sami Mol Biol Rep Original Article AIM: was to assess the role of C-KIT, TET1 and TET2 expression in the diagnosis and prognosis of acute myeloblastic leukemia (AML). METHODS: The expression levels of C-KIT, TET1 and TET2 were assessed in the bone marrow (BM) aspirate of 152 AML patients compared to 20 healthy control using quantitative real-time polymerase chain reaction (qRT-PCR). Data were correlated with the clinico-pathological features of the patients, response to treatment, disease-free survival (DFS), and overall survival (OS) rates. RESULTS: C-KIT, TET1 and TET2 were significantly upregulated in AML patients [0.25 (0–11.6), 0.0113 (0–3.301), and 0.07 (0–4); respectively], compared to the control group [0.013 (0.005–0.250), P < 0.001, 0.001 (0–0.006), P < 0.001, and 0.02 (0.008–0.055), P = 0.019; respectively]. The sensitivity, specificity, and area under curve of of C-KIT were (48.7%, 100%, 0.855; respectively, P = 0.001), and that of TET1 were (63.4%, 100%, 0.897; respectively, P = 0.001), while that of TET2 were (56.8%, 100%, 0.766; respectively, P = 0.019). When combining the three markers, the sensitivity was 77.5%, however it reached the highest sensitivity (78.6%) and specificity (100%) when combining both c-KIT + TET1 together for the diagnosis of AML. C-KIT overexpression associated with shorter DFS (P = 0.05) and increased incidence of relapse (P = 0.019). Lymph nodes involvement [HR = 2.200, P = 0.005] is an independent risk factor for shorter OS rate of AML patients. Increased BM blast % [HR = 7.768, P = 0.002], and FLT3-ITD mutation [HR = 2.989, P = 0.032] are independent risk factors for shorter DSF rate of the patients. CONCLUSION: C-KIT, TET1, and TET2 could be used as possible useful biomarkers for the diagnosis of AML. Springer Netherlands 2022-11-12 2023 /pmc/articles/PMC9884250/ /pubmed/36371552 http://dx.doi.org/10.1007/s11033-022-08000-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Nabil, Reem
Hassan, Naglaa M.
Abdellateif, Mona S.
Gawdat, Rania M.
Elshazly, Samar Sami
The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title_full The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title_fullStr The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title_full_unstemmed The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title_short The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
title_sort prognostic role of c-kit, tet1 and tet2 gene expression in acute myeloid leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884250/
https://www.ncbi.nlm.nih.gov/pubmed/36371552
http://dx.doi.org/10.1007/s11033-022-08000-0
work_keys_str_mv AT nabilreem theprognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT hassannaglaam theprognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT abdellateifmonas theprognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT gawdatraniam theprognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT elshazlysamarsami theprognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT nabilreem prognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT hassannaglaam prognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT abdellateifmonas prognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT gawdatraniam prognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia
AT elshazlysamarsami prognosticroleofckittet1andtet2geneexpressioninacutemyeloidleukemia